These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 33983627

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Balbuena-Merle R, Hendrickson JE.
    Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preventing antibody positive delayed hemolytic transfusion reactions in sickle cell disease: Lessons learned from a case.
    Rankin A, Webb J, Nickel RS.
    Transfus Med; 2022 Oct; 32(5):433-436. PubMed ID: 35318744
    [Abstract] [Full Text] [Related]

  • 8. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
    Thonier V.
    Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
    [Abstract] [Full Text] [Related]

  • 9. Regional registry of patient alloantibodies: first-year experience.
    Schwickerath V, Kowalski M, Menitove JE.
    Transfusion; 2010 Jul; 50(7):1465-70. PubMed ID: 20345565
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Red blood cell alloimmunization in sickle cell disease patients in Uganda.
    Natukunda B, Schonewille H, Ndugwa C, Brand A.
    Transfusion; 2010 Jan; 50(1):20-5. PubMed ID: 19821949
    [Abstract] [Full Text] [Related]

  • 12. Risk of hemolytic transfusion reactions following emergency-release RBC transfusion.
    Goodell PP, Uhl L, Mohammed M, Powers AA.
    Am J Clin Pathol; 2010 Aug; 134(2):202-6. PubMed ID: 20660321
    [Abstract] [Full Text] [Related]

  • 13. Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
    Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM.
    Transfusion; 2019 May; 59(5):1698-1705. PubMed ID: 30848512
    [Abstract] [Full Text] [Related]

  • 14. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Cox JV, Steane E, Cunningham G, Frenkel EP.
    Arch Intern Med; 1988 Nov; 148(11):2485-9. PubMed ID: 3142382
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
    Phou S, Costello C, Kopko PM, Allen ES.
    Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases.
    Natukunda B, Schonewille H, van de Watering L, Brand A.
    Vox Sang; 2010 Feb; 98(2):167-71. PubMed ID: 19708889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.